Views & Analysis

The life sciences industry has some unique challenges when it comes to compliance. But if you think third

Hidden compliance risks for life sciences companies

https://pharmaphorum.com/views-and-analysis/hidden-compliance-risks-for-life-sciences-companies/

Market Access/ Podcast/ Video/ Views & Analysis/ Views and analysis

Galapagos UK’s Michael Smyth on RNA-based tech: the pharmaphorum podcast

mike.smith@pharmaphorum.com Galapagos, HTA, Michael Smyth, podcast, rna 0 Comment

Episode 35 of the pharmaphorum podcast hears from Michael Smyth about Galapagos UK and joining the company as

Galapagos UK’s Michael Smyth on RNA-based tech: the pharmaphorum podcast

https://pharmaphorum.com/market-access-2/podcast-galapagos-uk-michael-smyth-rna/

Deep Dive/ Market Access/ Views & Analysis/ Views and analysis

Deep Dive: Market Access

mike.hammerton@pharmaphorum.com Boehringer Ingelheim, Brexit, Deep Dive, digital health, HTA, market access, NICE, patient centricity, patient engagement, sales 0 Comment

It’s fair to say this is the most interesting time ever for market access. Not only has COVID

Deep Dive: Market Access

https://pharmaphorum.com/views-analysis-market-access/deep-dive-market-access-2021/

Market Access/ Views & Analysis/ Views and analysis

The next five years of NICE: Challenges, opportunities, and the future of technology assessment

Amanda Barrell digital health, health inequality, health technology evaluation, mental health, NICE 0 Comment

If NICE is to remain a “beacon of evidence-based medicine”, it must become more agile, more flexible, and

The next five years of NICE: Challenges, opportunities, and the future of technology assessment

https://pharmaphorum.com/views-and-analysis/the-next-five-years-of-nice-challenges-opportunities-and-the-future-of-technology-assessment/

medicine-human-holding-drugs-tablets-16x9

Market Access/ Views & Analysis/ Views and analysis

Three pillars of post-pandemic launch excellence

Catherine Longworth IQVIA, launch excellence 0 Comment

IQVIA’s Sarah Rickwood reviews the launch of innovative medicines in 2020 and outlines three key pillars of activity

Three pillars of post-pandemic launch excellence

https://pharmaphorum.com/views-and-analysis/three-pillars-of-post-pandemic-launch-excellence/

Market Access/ Views & Analysis/ Views and analysis

Global impact: How regulatory affairs is shaping development of cutting-edge pharma innovation

mike.hammerton@pharmaphorum.com Astellas, market access, Regulatory affairs 0 Comment

When it comes to developing cutting-edge innovations, Astellas aims to be at the forefront. The pharma organisation prides

Global impact: How regulatory affairs is shaping development of cutting-edge pharma innovation

https://pharmaphorum.com/views-and-analysis/global-impact-how-regulatory-affairs-is-shaping-development-of-cutting-edge-pharma-innovation/

Market Access/ Views & Analysis/ Views and analysis

NICE methods and process review aims to create fertile ground for innovation

Amanda Barrell ABPI, NICE, NICE Methods Review 0 Comment

The way NICE reviews new medicines is about to go through its biggest change in years – but

NICE methods and process review aims to create fertile ground for innovation

https://pharmaphorum.com/views-and-analysis/nice-methods-and-process-review-aims-to-create-fertile-ground-for-innovation/

Market Access/ Views & Analysis/ Views and analysis

The Brexit deal; shot in the arm or kick in the teeth for the pharma sector?

Catherine Longworth Brexit, EU 0 Comment

The UK Government and EU Commission trumpeted their Brexit trade deal, struck at the end of December, as

The Brexit deal; shot in the arm or kick in the teeth for the pharma sector?

https://pharmaphorum.com/market-access-2/the-brexit-deal-for-the-pharma-sector/

Digital/ Market Access/ R&D/ Views & Analysis/ Views & Analysis/ Views & Analysis/ Views and analysis

Life sciences must become cloud-first to seize the science of tomorrow

mike.hammerton@pharmaphorum.com Accenture, Cloud, data 0 Comment

If the power of the life sciences industry to innovate and collaborate were ever in doubt, the speed

Life sciences must become cloud-first to seize the science of tomorrow

https://pharmaphorum.com/views-analysis-digital/life-sciences-must-become-cloud-first-to-seize-the-science-of-tomorrow/

«‹ 7 8 9 10 ›»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com

Trending

Views & Analysis

Login